Personalis (NASDAQ:PSNL – Get Rating) is set to release its earnings data after the market closes on Wednesday, May 4th. Analysts expect Personalis to post earnings of ($0.57) per share for the quarter. Personalis has set its FY 2022 guidance at EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.
Personalis (NASDAQ:PSNL – Get Rating) last issued its earnings results on Thursday, February 24th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.06. Personalis had a negative net margin of 76.29% and a negative return on equity of 19.72%. The company had revenue of $20.68 million for the quarter, compared to the consensus estimate of $20.70 million. During the same period in the previous year, the firm earned ($0.34) earnings per share. On average, analysts expect Personalis to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of PSNL stock opened at $5.75 on Wednesday. The firm’s 50-day moving average is $8.34 and its two-hundred day moving average is $12.45. Personalis has a 12 month low of $5.70 and a 12 month high of $28.47. The company has a market capitalization of $259.81 million, a PE ratio of -3.89 and a beta of 1.56.
In other news, CFO Aaron Tachibana sold 4,511 shares of the company’s stock in a transaction on Wednesday, March 2nd. The stock was sold at an average price of $10.18, for a total transaction of $45,921.98. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Lightspeed Venture Partners Se bought 48,989 shares of the company’s stock in a transaction that occurred on Wednesday, March 2nd. The stock was acquired at an average cost of $9.96 per share, for a total transaction of $487,930.44. The disclosure for this purchase can be found here. Insiders have sold 5,687 shares of company stock worth $57,717 in the last ninety days. Corporate insiders own 7.50% of the company’s stock.
Large investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA increased its holdings in Personalis by 133.5% in the third quarter. BNP Paribas Arbitrage SA now owns 9,057 shares of the company’s stock valued at $174,000 after buying an additional 5,178 shares during the last quarter. Vident Investment Advisory LLC purchased a new position in shares of Personalis during the fourth quarter worth about $183,000. Parametric Portfolio Associates LLC grew its holdings in shares of Personalis by 12.1% during the fourth quarter. Parametric Portfolio Associates LLC now owns 15,105 shares of the company’s stock worth $216,000 after purchasing an additional 1,632 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Personalis by 72.6% during the second quarter. Invesco Ltd. now owns 15,749 shares of the company’s stock worth $399,000 after purchasing an additional 6,623 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Personalis by 59.2% during the fourth quarter. Legal & General Group Plc now owns 22,069 shares of the company’s stock worth $315,000 after purchasing an additional 8,208 shares during the last quarter. 67.63% of the stock is currently owned by hedge funds and other institutional investors.
About Personalis (Get Rating)
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.
- Get a free copy of the StockNews.com research report on Personalis (PSNL)
- Las Vegas Sands Stock Could be a Winning Bet Down Here
- Newmont Corporation is the Same as It’s Always Been Which is Why It’s a Buy
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.